Table 3 Organization and establishment
Characteristics | Organizations producing CPGs (n = 31) | Organizations producing HTAs (n = 19) | Organizations producing CPGs and HTAs (n = 45) | Organizations supporting government policymaking (n = 57) |
|---|---|---|---|---|
Type of product produced | ||||
Reported also providing direct support to policymakers for developing health policy | 17 (55%) | 16 (85%) | 35 (78%) | - |
Reported also producing clinical practice guidelines | - | - | - | 17 (30%) |
Reported also producing HTAs | - | - | - | 11 (19%) |
Types of services undertaken in response to requests from public policymakers* | ||||
Identify primary research | - | - | - | 36 (63%) |
Identify systematic reviews of research | - | - | - | 31 (54%) |
Identify clinical practice guidelines, HTAs or other prescriptive research-based documents | - | - | - | 24 (42%) |
Undertake short-term research projects | - | - | - | 45 (79%) |
Undertake systematic reviews of research | - | - | - | 38 (67%) |
Commission systematic reviews of research | - | - | - | 17 (30%) |
Either undertake systematic reviews of research or commission systematic reviews of research | - | - | - | 41 (72%) |
Convene expert meetings to discuss available research | - | - | - | 47 (82%) |
Other | - | - | - | 18 (32%) |
Type of organization | ||||
Academic institution | 7 (23%) | 7 (37%) | 11 (24%) | 21 (37%) |
Disease-specific association | 1 (3%) | 0 (0%) | 1 (2%) | 0 (0%) |
Professional association | 14 (45%) | 2 (11%) | 4 (9%) | 3 (5%) |
Government agency | 9 (29%) | 12 (63%) | 22 (49%) | 22 (39%) |
International agency | 0 (0%) | 0 (0%) | 3 (7%) | 7 (12%) |
Other | 8 (26%) | 2 (11%) | 7 (16%) | 18 (32%) |
Source of funding* | ||||
Biomedical or other for-profit company | 7 (23%) | 1 (5%) | 6 (13%) | 6 (11%) |
Government | 17 (55%) | 18 (95%) | 38 (84%) | 45 (79%) |
Other | 15 (48%) | 3 (16%) | 20 (44%) | 38 (67%) |
Examples from other countries helpful in establishing the organization | ||||
Yes | 18 (58%) | 14 (74%) | 24 (53%) | 30 (53%) |
No | 8 (26%) | 0 (0%) | 15 (33%) | 17 (30%) |
Not reported | 4 (13%) | 4 (21%) | 6 (13%) | 7 (12%) |